Ones To Watch News
Refine Search
Biotechnology
The US Food and Drug Administration (FDA) yesterday granted accelerated approval to Bizengri (zenocutuzumab-zbco; Zeno) from Dutch firm Merus NV, whose shares edged up 1.8% to $46.32 on the news. 5 December 2024
Biotechnology
Massachusetts, USA-based clinical stage biotech Rgenta Therapeutics, which is developing a new class of oral small molecules targeting RNA for oncology and neurological disorders, announced today that it has entered into a multi-year, multi-target strategic research alliance with the UK’s GSK. 4 December 2024
Biotechnology
Shares of US precision medicines firm Relay Therapeutics closed down 6% at $4.39 yesterday after announced a licensing deal for its lirafugratinib. 4 December 2024
Biotechnology
Privately-held Dewpoint Therapeutics, a Boston, USA, biotech developing therapeutics by targeting biomolecular condensates, has entered into a strategic research collaboration with Japan’s Mitsubishi Tanabe Pharma Corporation (MTPC). 4 December 2024
Biotechnology
Chinese biotech Duality Biologics yesterday revealed that it has entered into an exclusive option agreement with UK pharma major GSK for a potentially best-in-class ADC candidate, DB-1324. 4 December 2024
Biotechnology
Boston-based AI Proteins, a biotech that uses computational de novo protein design to create therapeutic miniproteins, has entered a research collaboration and option agreement with US pharma major Bristol Myers Squibb. 4 December 2024
Biotechnology
Refoxy Pharmaceuticals has raised 9.1 million euros ($10 million) in seed-extension financing led by Boehringer Ingelheim Venture Fund (BIVF), with support from Apollo Health Ventures and others. 4 December 2024
Pharmaceutical
Japanese drugmaker Ono Pharmaceutical has entered into a drug discovery collaboration agreement with privately-held Canadian firm Congruence Therapeutics. 4 December 2024
Biotechnology
Dutch privately held Amarna Therapeutics, which specializes in transformative gene therapies, has entered into a strategic collaboration with Sweden-based NorthX Biologics, a leading biologics manufacturing partner. 4 December 2024
Pharmaceutical
Danish drug developer Antag Therapeutics, which is pioneering novel treatments for obesity, today announced the closing of an 80 million euros ($83.8 million) Series A financing. 4 December 2024
Pharmaceutical
Maze Therapeutics, a California-based biotech, has raised $115 million in a series D financing round co-led by Frazier Life Sciences and Deep Track Capital. 4 December 2024
Biotechnology
US antiviral giant Gilead Sciences has entered into an exclusive option and license agreement with Germany’s Tubulis to discover and develop an antibody-drug conjugate (ADC) against a solid tumor target. 3 December 2024
Pharmaceutical
US biopharma Olema Pharmaceuticals has announced a clinical trial collaboration and supply agreement with Swiss pharma giant Novartis in frontline metastatic breast cancer. 3 December 2024
Biotechnology
Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized neoantigen cancer immunotherapies, has announced the appointment of Eckhard Niemeier as its chief business officer (CBO). 3 December 2024
Biotechnology
Nearly seven years after its founding, Senti Biosciences has announced promising results from its Phase I trial for SENTI-202. 3 December 2024
Pharmaceutical
Swedish pharma Orexo and Germany-based digital therapeutics company GAIA have decided to end their partnership agreement for the former firm to commercialize the digital mental health program for depression, Deprexis, in the USA. 2 December 2024
Biotechnology
Netherlands and USA-based Merus has inked an exclusive licensing accord with privately-held Partner Therapeutics (PTx), for the right to commercialize zenocutuzumab (Zeno) for the treatment of NRG1 fusion-positive (NRG1+) cancer in the USA. 2 December 2024
Pharmaceutical
Switzerland-based Novocure saw its shares leap 38% to $27.64 as it revealed positive results from the pivotal, Phase III PANOVA-3 trial, demonstrating a statistically-significant improvement in median overall survival (mOS) versus control. 2 December 2024
Biotechnology
Shares of Israel-based clinical-stage company Purple Biotech jumped 9.5% to 6.90 shekels after it announced positive final results from the randomized Phase II study of its lead oncology drug, CM24, a humanized monoclonal antibody that blocks CEACAM1, in patients with pancreatic ductal adenocarcinoma (PDAC). 2 December 2024
Biotechnology
Swedish immuno-oncology firm Alligator Bioscience has announced a major restructuring to prioritize its lead asset, mitazalimab. 2 December 2024
Pharmaceutical
China-based Jiangsu Hengrui Pharma and US start-up Kailera Therapeutics, which is advancing a broad pipeline of next-generation therapies for the treatment of obesity, today announced positive top-line data from Hengrui’s Phase III clinical trial (HRS9531-301) of once-weekly subcutaneous injection of HRS9531, a novel dual GLP-1/GIP receptor agonist, in individuals living with obesity or overweight in China. 15 July 2025
Pharmaceutical
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has today approved Ekterly (sebetralstat) 0for the treatment of hereditary angioedema (HAE) attacks in adults and adolescents aged 12 years and older. 15 July 2025
Biotechnology
US biotech Tract Bio has appointed Chris Galloway as chief medical and development officer, as it prepares for an investigational new drug filing for its lead oncology candidate, TP-101, within the next 18 months. The Boston-based company is also expanding its board with two senior figures from the oncology and biotech world: Mark Adler and Kristiina Vuori. 15 July 2025
Biotechnology
Japanese drugmaker Otsuka Pharmaceutical has signed a deal to acquire Cantargia’s CAN10 program in a transaction worth up to $613 million. The move hands Otsuka global rights to an early-stage antibody therapy targeting IL1RAP, as the company doubles down on its autoimmune disease pipeline. 15 July 2025
Biotechnology
Swiss clinical-stage CNS disease specialist Synendos Therapeutics has named Dr George Garibaldi as its chief medical officer (CMO). 15 July 2025
Biotechnology
USA-based Uniquity Bio has appointed industry veteran Will Kane as its president and chief executive. 15 July 2025
Pharmaceutical
South Korean biotech Illimis Therapeutics has raised 58 billion won ($42 million) in a series B round to advance its GAIA platform into the preclinical stage and expand its drug development programs targeting Alzheimer’s disease and immune disorders. 14 July 2025
Pharmaceutical
US biotech Crinetics Pharmaceuticals has released new data on its investigational oral therapy Palsonify (paltusotine), supporting its potential as a convenient alternative to monthly injections for patients with acromegaly. 14 July 2025
Biotechnology
California-based Renasant Bio announced its launch to advance next-generation disease-modifying treatments for autosomal dominant polycystic kidney disease (ADPKD), the leading genetic cause of end-stage renal failure. 13 July 2025
Pharmaceutical
US pharma giant Merck & Co today revealed it has made a bid to acquire UK-based lung therapy company Verona Pharma, sending the latter’s shares up 20.4% to $104.61 in pre-market activity. 13 July 2025
Biotechnology
US CAR-T focused biotech CARGO Therapeutics today announced that it has entered into a definitive merger agreement with Concentra Biosciences, initially worth roughly $200 million. The news sent CARGO’s stock up as much as 9.6% to $4.81 in pre-market activity. 12 July 2025
Pharmaceutical
Nuclidium, a radiopharma company developing a proprietary copper-based theranostic platform, has announced the successful closing of its Series B financing round, raising 79 million Swiss francs ($99 million). 11 July 2025
Biotechnology
BrainXell, a US biotechnology company developing iPSC-based CNS disease models and regenerative cell therapies, has announced the appointment of Katherine Vega Stultz as its new chief executive and board director. 11 July 2025
Biotechnology
Chinese cell therapy developer NK CellTech has raised nearly 100 million renminbi ($14 million) in an extended series A+++ round to support the clinical development of its flagship NK cell therapies and broaden its pipeline. 11 July 2025
Biotechnology
French biotech Osivax has published results from a Phase IIa trial showing that its lead candidate OVX836, a broad-spectrum influenza vaccine, demonstrated a strong safety profile and immune response when administered alongside a conventional flu shot. 10 July 2025
Biotechnology
China-based biotech Biocytogen has signed a global licensing agreement with oncology-focused BeOne Medicines, handing over rights to multiple fully human antibodies discovered through its proprietary RenMice platform. 10 July 2025
Pharmaceutical
Secarna Pharmaceuticals has formed a strategic collaboration with Vect-Horus aimed at advancing RNA-targeted therapies capable of crossing the blood-brain barrier, a key hurdle in treating central nervous system disorders. 10 July 2025
Biotechnology
Radiant Biotherapeutics, a Canadian biotech advancing multi-specific, multi-affinity antibody (Multabody) therapeutics in cancer and autoimmune diseases, has announced the appointment of Deborah Geraghty as president and chief executive. 9 July 2025
Biotechnology
Dutch privately held Amarna Therapeutics, which specializes in transformative gene therapies announced the formalization of an agreement with biologics manufacturing partner, Sweden’s NorthX Biologics, to accelerate the development of Nimivec, Amarna’s next-generation gene therapy platform targeting immune-mediated diseases. 9 July 2025
Pharmaceutical
Shares of US biopharma Rhythm Pharmaceuticals rose 27.4% to $82.96 in early trading today, as it announced positive top-line results from its Phase II trial evaluating bivamelagon (formerly LB54640), an investigational oral melanocortin-4 receptor (MC4R) agonist, in patients with acquired hypothalamic obesity. 9 July 2025
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze